Treats bronchoconstriction. ANDA 213762, held by Adaptis. Arformoterol Tartrate.
As of Nov 22, 2026, ANDA 213762 (Arformoterol Tartrate), held by Adaptis, was first approved by FDA on Jun 22, 2021, with 0 approved supplements and 0 published complete response letters.
Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 22, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Arformoterol TartrateEQ 0.015MG BASE/2ML · solution;inhalation | Arformoterol Tartrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters